* Castle Biosciences Inc CSTL.OQ reported quarterly
adjusted
earnings of 31 cents per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -70 cents. The mean expectation of
nine analysts for the quarter was for a loss of 27 cents per
share. Wall Street expected results to range from -46 cents
to -10 cents per share.
* Revenue rose 73.5% to $87.00 million from a year ago;
analysts
expected $69.34 million.
* Castle Biosciences Inc's reported EPS for the quarter was
31
cents.
* The company reported quarterly net income of $8.92
million.
* Castle Biosciences Inc shares had risen by 2.3% this
quarter and
gained 3.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 8.5%
in the last three months.
* In the last 30 days, there have been no negative revisions
of
earnings estimates
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 9 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the medical
equipment,
supplies & distribution peer group is also "strong buy"
Wall Street's median 12-month price target for Castle
Biosciences Inc is $34.00
This summary was machine generated from LSEG data August 5 at
09:22 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.27 0.31 Beat
Mar. 31 2024 -0.33 -0.09 Beat
Dec. 31 2023 -0.54 -0.10 Beat
Sep. 30 2023 -0.76 -0.26 Beat